BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 26338898)

  • 1. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
    Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
    J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of florbetapir-PET for imaging beta-amyloid pathology.
    Clark CM; Schneider JA; Bedell BJ; Beach TG; Bilker WB; Mintun MA; Pontecorvo MJ; Hefti F; Carpenter AP; Flitter ML; Krautkramer MJ; Kung HF; Coleman RE; Doraiswamy PM; Fleisher AS; Sabbagh MN; Sadowsky CH; Reiman EP; Zehntner SP; Skovronsky DM;
    JAMA; 2011 Jan; 305(3):275-83. PubMed ID: 21245183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
    Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
    J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of 18F-florbetapir PET: comparison of two analysis methods.
    Hutton C; Declerck J; Mintun MA; Pontecorvo MJ; Devous MD; Joshi AD;
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):725-32. PubMed ID: 25652817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images.
    Carbonell F; Zijdenbos AP; Charil A; Grand'Maison M; Bedell BJ;
    J Nucl Med; 2015 Sep; 56(9):1351-8. PubMed ID: 26135108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracer-specific reference tissues selection improves detection of
    Li Y; Ng YL; Paranjpe MD; Ge Q; Gu F; Li P; Yan S; Lu J; Wang X; Zhou Y;
    Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
    Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
    Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on
    Reith F; Koran ME; Davidzon G; Zaharchuk G;
    AJNR Am J Neuroradiol; 2020 Jun; 41(6):980-986. PubMed ID: 32499247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visualization and Quantification of 3-Dimensional Stereotactic Surface Projections for 18F-Flutemetamol PET Using Variable Depth.
    Lilja J; Thurfjell L; Sörensen J
    J Nucl Med; 2016 Jul; 57(7):1078-83. PubMed ID: 26912445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study.
    Park MA; Padera RF; Belanger A; Dubey S; Hwang DH; Veeranna V; Falk RH; Di Carli MF; Dorbala S
    Circ Cardiovasc Imaging; 2015 Aug; 8(8):. PubMed ID: 26259579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
    Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
    Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
    Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
    Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
    Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimisation and usefulness of quantitative analysis of
    Fakhry-Darian D; Patel NH; Khan S; Barwick T; Svensson W; Khan S; Perry RJ; Malhotra P; Carswell CJ; Nijran KS; Win Z
    Br J Radiol; 2019 Sep; 92(1101):20181020. PubMed ID: 31017465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.